We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Provectus Reports on Second End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma
News

Provectus Reports on Second End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma

Provectus Reports on Second End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma
News

Provectus Reports on Second End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Provectus Reports on Second End-of-Phase 2 Meeting with U.S. FDA to Define Pathway to Licensure of PV-10 for Metastatic Melanoma"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Provectus is seeking consensus on design of the study to support licensure of PV-10 for its melanoma indication.

Craig Dees, Ph.D., CEO of Provectus said, “This meeting was extremely productive in defining the threshold the Agency will require for approval in oncology. Based on the recommendations of senior Agency officials during this meeting we plan to request a third end-of-Phase 2 meeting very soon to finalize our design since a much quicker iteration is now probable. We expect this next meeting will provide the remaining groundwork to allow us to reach a consensus on a design suitable for Special Protocol Assessment (SPA). The SPA objective is the expected ultimate outcome for both the Agency and the Company. The input of the Agency will help us complete design of our study to meet current and likely future standards for approval.”

Dr. Dees concluded, “We are also assessing whether a second Phase 3 RCT, tailored to meet the regulatory requirements of Australia, would be helpful in accelerating approval in that important market. We are fortunate that our capital resources afford flexibility in optimizing our development plan to maximize likelihood of approval in the unique, major melanoma markets in the U.S., Australia and the EU.”

Advertisement